EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom

Value in Health

Volumn 21, Issue 1, 2018, Pages 49-56

  Hernandez Alava, Monica ^a   Wailoo, Allan ^a   Grimm, Sabine ^b   Pudney, Stephen ^a   Gomes, Manuel ^c   Sadique, Zia ^c   Meads, David ^d   O'Dwyer, John ^d   Barton, Garry ^e   Irvine, Lisa ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

cost effectiveness; EQ 5D; health utility

Indexed keywords

ADULT; ANXIETY DISORDER; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENMARK; DEPRESSION; DIABETES MELLITUS; ENGLAND; EUROQOL FIVE DIMENSIONAL 3L QUESTIONNAIRE; EUROQOL FIVE DIMENSIONAL 5L QUESTIONNAIRE; EXPLANATORY VARIABLE; FEMALE; HUMAN; HUMAN ACTIVITIES; ITALY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL TECHNOLOGY; MORTALITY; NETHERLANDS; OBSERVATIONAL STUDY; PAIN; PERSONALITY DISORDER; PHYSICAL MOBILITY; POLAND; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RHEUMATIC DISEASE; SCOTLAND; SELF CARE; UNITED KINGDOM; COST BENEFIT ANALYSIS; HEALTH STATUS; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOMETRY; QUESTIONNAIRE; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; ENGLAND; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 85031665559     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2017.09.004     Document Type: Article

References (24)

1. Herdman, M., Gudex, C., Lloyd, A., et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20 (2011), 1727–1736.
2. Devlin, N., Shah, K., Feng, Y., et al. Valuing health-related quality of life: an EQ-5D-5L value set for England. 2016, OHE Research Paper 16/01, Office of Health Economics, London.
3. Xie, F., Pullenayegum, E., Gaebel, K., et al. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care 54 (2016), 98–105.
4. Shiroiwa, T., Ikeda, S., Noto, S., et al. Comparison of value set based on DCE and/or TTO data: scoring for EQ-5D-5L health states in Japan. Value Health 19 (2016), 648–654.
5. Augustovski, F., Rey-Ares, L., Irazola, V., et al. An EQ-5D-5L value set based on Uruguayan population preferences. Qual Life Res 25 (2016), 323–333.
6. Versteegh, M.M., Vermeulen, K.M., Evers, S.M., et al. Dutch tariff for the five-level version of EQ-5D. Value Health 19 (2016), 343–352.
7. Kim, S.H., Ahn, J., Ock, M., et al. The EQ-5D-5L valuation study in Korea. Qual Life Res 25 (2016), 1845–1852.
8. Feng Y, Devlin N, Shah K, et al. New methods for modelling EQ-5D-5L value sets: an application to English data. Available from: https://www.ohe.org/publications/new-methods-modelling-eq-5d-5l-value-sets-application-english-data. [Accessed May 23, 2017].
9. Wolfe, F., Michaud, K., The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology 50 (2011), 16–24.
10. Hernandez Alava, M., Pudney, S., Econometric modelling of multiple self-reports of health states: The switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis. J Health Econ 55 (2017), 139–152.
11. Choy, E.H.S., Smith, C.M., Farewell, V., et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67 (2008), 656–663.
12. Wailoo, A., Hernandez Alava, M., Scott, I., et al. Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford) 53 (2014), 1773–1777.
13. Latimer, N.R., Dixon, S., Palmer, R., Cost-utility of self-managed computer therapy for people with aphasia. Int J Technol Assess Health Care 29 (2013), 402–409.
14. IMPROVE Trial Investigators. Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30 day outcomes from IMPROVE randomised trial. BMJ, 348, 2014, f7661.
15. Ford, H.E.R., Marshall, A., Bridgewater, J.A., et al. COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol 15 (2014), 78–86.
16. Hillmen, P., Milligan, D., Schuh, A., et al. Results of the randomised phase II NCRI ARCTIC (Attenuated dose Rituximab with ChemoTherapy In CLL) trial of low dose rituximab in previously untreated CLL. Blood, 122, 2013, 1639.
17. Howard, D.R., Munir, T., McParland, L., et al. Clinical effectiveness and cost-effectiveness results from the randomised, phase IIB trial in previously untreated patients with chronic lymphcytic leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with fludarabine, cyclophosphamide, mitoxantrone and low dose rituximab (FCM-miniR): the Attenuated dose Rituximab with ChemoTherapy In CLL (ARCTIC) trial. Health Technol Assess 21 (2017), 1–374.
18. Blyth, A., Maskrey, V., Notley, C., et al. Effectiveness and economic evaluation of self-help educational materials for the prevention of smoking relapse: randomised controlled trial. Health Technol Assess 19 (2015), 1–70.
19. Ahern, A.L., Aveyard, P.N., Halford, J.C., et al. Weight loss referrals for adults in primary care (WRAP): protocol for a multi-centre randomised controlled trial comparing the clinical and cost-effectiveness of primary care referral to a commercial weight loss provider for 12 weeks, referral for 52 weeks, and a brief self-help intervention [ISRCTN82857232]. BMC Public Health, 14, 2014, 620.
20. Gershlick, A.H., Khan, J.N., Kelly, D.J., et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 65 (2015), 963–972.
21. Dolan, P., Modeling valuations for EuroQol health states. Med Care 35 (1997), 1095–1108.
22. Devlin, N., Shah, K., Feng, Y., et al. Valuing Health Related Quality of Life: An EQ-5D-5L Value Set for England. Technical Report 16.02. 2016, Health Economics and Decision Science, University of Sheffield, Sheffield, UK.
23. Mulhern B, Feng Y, Shah K, et al. Comparing the UK EQ-5D-3L and the English EQ-5D-5L value sets. OHE Research Paper 17/02. Available from: https://www.ohe.org/publications/comparing-uk-eq-5d-3l-and-english-eq-5d-5l-value-sets. [Accessed June 20, 2017].
24. Van Hout, B., Janssen, M.F., Feng, Y., et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15 (2012), 708–715.